Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
- Capelleveen, J.C. van
- Kastelein, J.J.P.
- Zwinderman, A.H.
- Deventer, S.J.H. van
- Collins, H.L.
- Adelman, S.J.
- Round, P.
- Ford, J.
- Rader, D.J.
- Hovingh, G.K.
DOIAbstract
CONCLUSION: TA-8995 dose dependently increased not only total and non-ABCAl-specific CEC but also ABCAl-specific CEC and preBeta-1 HDL particle levels. These findings suggest that TA-8995 not only increases HDL-C levels but also promotes functional properties of HDL particles. This CETP inhibitor driven preBeta-1 HDL increase is an important predictor of both ABCA1 and total CEC increase, independent of HDL-C increase. Whether these changes in HDL particle composition and functionality have a beneficial effect on cardiovascular outcome requires formal testing in a cardiovascular outcome trial. (C) 2016 National Lipid Association. All rights reserved
Add to ORKG